CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Beginning June 1, 2020 all 5 CTS laboratories will being transitioning from the Grifols Procleix Ult...
Reminder - Five CTS Forms will be updated on Monday September 2, 2019. Some of the forms are posted ...
Dr. Buff Mair is the new CTS Medical Director and replaces Dr. German Leparc who retired at the begi...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...
The FDA Guidance ZIKV video for the webinar held on 08/15/18 has been posted in the Wh...
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...